Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

On Monday, Johnson & Johnson (NYSE:JNJ) announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn’s ...

After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...

Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear ...

Phase 3b trial evaluating Tremfya (guselkumab) in low body surface area plaque psoriasis found the treatment improved clearance.

The anti-IL-23 monoclonal antibody, called picankibart, was shown to clear or nearly clear all lesions after 16 weeks among 48.2% of the 82 participating Chinese patients that were classified as ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...

(RTTNews) - Johnson & Johnson (JNJ) Monday announced positive results from Phase 3 GRAVITI study of Tremfya as both induction and maintenance therapy in Crohn's disease, a type of inflammatory ...

New phase 3b data reveal significant skin clearance in historically underserved patients with moderate plaque psoriasis, offering hope for improved treatment outcomes.

Tremfya (guselkumab) is a prescription drug that’s used to treat certain autoimmune conditions, including plaque psoriasis. Tremfya can cause side effects that range from mild to serious.

The FDA approved Tremfya in September 2024 for moderately to severely active ulcerative colitis. The application for moderately to severely active Crohn's disease is currently under FDA review.

At week 16, an IGA score of 0 or 1 was met for guselkumab vs placebo in scalp (75.0% vs 14.5%), face (87.8% vs 28.6%), intertriginous (86.5% vs 28.8%) and genital (78.0% vs 37.5%). A phase 3b ...